$0.3321
-0.0144[-4.16%]
At close: Apr 26
$0.3321
0[0.00%]
After Hours: 6:03PM EDT
Latest News for Clene Stock (NASDAQ:CLNN)
Clene Stock (NASDAQ: CLNN)
Categories: All
Friday, April 19, 2024
Wednesday, April 17, 2024
- The Analyst Verdict: Clene In The Eyes Of 5 ExpertsBenzinga Insights - Apr 17, 2024, 4:02PM
- 12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga Insights - Apr 17, 2024, 8:08AM
- HC Wainwright & Co. Reiterates Buy on Clene, Maintains $7 Price TargetBenzinga Newsdesk - Apr 17, 2024, 6:42AM
- Why INVO Bioscience Shares Are Trading Higher By Around 73%; Here Are 20 Stocks Moving PremarketAvi Kapoor - Apr 17, 2024, 6:13AM
Tuesday, April 16, 2024
- 12 Health Care Stocks Moving In Tuesday's After-Market SessionBenzinga Insights - Apr 16, 2024, 4:31PM
- Clene shares are trading higher after the company announced Phase 2 VISIONARY-MS long term extension study results at the 2024 American Academy of Neurology Annual Meeting.Benzinga Newsdesk - Apr 16, 2024, 4:25PM
- Clene Highlights Presentation Of Phase 2 VISIONARY-MS Trial Data At 2024 American Academy of Neurology Annual Meeting; Says 'Long-term CNM-Au8 treatment, encompassing up to three years, was well-tolerated; no significant safety findings were observed'Benzinga Newsdesk - Apr 16, 2024, 4:06PM
Wednesday, March 20, 2024
Friday, March 15, 2024
Wednesday, March 13, 2024
- Breaking Down Clene: 4 Analysts Share Their ViewsBenzinga Insights - Mar 13, 2024, 3:00PM
- HC Wainwright & Co. Reiterates Buy on Clene, Maintains $7 Price TargetBenzinga Newsdesk - Mar 13, 2024, 12:44PM
- Clene: Q4 Earnings InsightsBenzinga Insights - Mar 13, 2024, 9:40AM
- Clene's Cash, Cash Equivalents And Marketable Securities Of $35M As Of December 31, 2023, Will Be Sufficient To Fund Its Operations Into The Fourth Quarter Of 2024Benzinga Newsdesk - Mar 13, 2024, 8:11AM
- Clene FY GAAP EPS $(0.47) Misses $(0.46) Estimate, Sales $654.00K Beat $557.00K EstimateBenzinga Newsdesk - Mar 13, 2024, 8:10AM
Monday, March 11, 2024
Thursday, February 29, 2024
Thursday, February 22, 2024
Wednesday, February 14, 2024
Tuesday, February 13, 2024
Monday, January 08, 2024
- Clene shares are trading higher after the company announced improvement in vision and cognition with CNM-Au8 treatment in VISIONARY-MS trial long-term open label extension.Benzinga Newsdesk - Jan 8, 2024, 3:55PM
- Clene Reports Improvement in Vision and Cognition With CNM-Au8 Treatment in VISIONARY-MS Trial Long-Term Open Label ExtensionBenzinga Newsdesk - Jan 8, 2024, 7:22AM
Thursday, December 21, 2023
- Clene shares are trading lower after the FDA determined that the initial findings on biomarker NfL reduction from the Phase 2 programs were insufficient to support accelerated approval.Benzinga Newsdesk - Dec 21, 2023, 3:12PM
- Nasdaq Gains 100 Points; CarMax Earnings Top ViewsAvi Kapoor - Dec 21, 2023, 2:23PM
- FDA Refuses Neurology-Focused Clene's Accelerated Approval For Amyotrophic Lateral Sclerosis Treatment, Shares FallVandana Singh - Dec 21, 2023, 1:02PM
- Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionAvi Kapoor - Dec 21, 2023, 1:01PM
- 12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga Insights - Dec 21, 2023, 12:32PM
- Crude Oil Moves Lower; Micron Issues Strong ForecastAvi Kapoor - Dec 21, 2023, 11:59AM
- Dow Jumps 250 Points; US Weekly Jobless Claims Edge HigherAvi Kapoor - Dec 21, 2023, 9:48AM
- HC Wainwright & Co. Reiterates Buy on Clene, Maintains $7 Price TargetBenzinga Newsdesk - Dec 21, 2023, 8:34AM
- Clene Reports New Data From 12-Month Long-Term Open Label Extension Of CNM-Au8 Treatment Arm In HEALEY ALS Platform TrialBenzinga Newsdesk - Dec 21, 2023, 7:04AM
- Clene Provides Update On ALS Clinical Development Meeting With FDA; Says FDA Determined That Initial Findings On Biomarker NfL Reduction From Phase 2 Programs Were InsufficientBenzinga Newsdesk - Dec 21, 2023, 7:02AM
Tuesday, December 19, 2023
Thursday, December 14, 2023
Tuesday, November 07, 2023
Wednesday, October 25, 2023
Thursday, October 05, 2023
Thursday, September 28, 2023
Tuesday, September 26, 2023
Monday, September 25, 2023
- Clene's Neurogenerative Candidate Shows Potential For Improved Long-Term SurvivalVandana Singh - Sep 25, 2023, 4:25PM
- Clene Announced Long-term Follow-up Data For Patients Treated With CNM-au8 30Mg For Up To 133 Weeks In The HEALEY ALS Platform Trial, Showing Improved Survival With A 49% Decreased Risk Of DeathBenzinga Newsdesk - Sep 25, 2023, 7:05AM